Jim	consulted for Janssen Scientific Affairs and Merck and has grant funding from Kite Pharma.
Wingard	consulted for Celgene, Merck, Cidara, Takeda
Hashmi	honoraria from Novartis, Mallinckrodt, Pfizer, and Janssen; honoraria from Novartis, Mallinckrodt, Pfizer, and Janssen; Consulting for Novartis, Kite, Juno, Takeda, CRISPR
Cerny	Consultant/Ad Board Member Pfizer Inc, Amgen Inc., Jazz Pharmaceuticals; DSMB Member-Allovir Inc., Stocks- Actinium Pharmaceuticals, Bluebird Bio/SeventyFour Inc., Dynavax Pharma, Atyr Pharma, Gamida Cell, Miragen Therapeutics, Mustang Bio, Novavax, Ovid Therapeutics, Sorrento Therapeutics, TG Therapeutics, Vaxart Inc, and Veru Inc
Stiff	Consulting for CRISPR, Pfizer, Morphosys; grant receipts from Gamida Cell, Amgen, Pfizer, Gilead, Incyte, Karyopharm, Cellectar, Bristol- Myers Squibb, Johnson and Johnson, Alovir, Atara Seattle Genetics
Holten	Research funding from Incyte and Vitrac Therapeutics. Clinical trial adjudication for CSL Behring. Consultantion for Generon and Ossium.
Others	No COI to report